Observational studyClinical and translational medicine2025

Response-adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A retrospective observational study.

Rong Shen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.